An interventional study of Lateral decubitus position group (Group L) and Supine position group (Group S) in Postoperative Hypoxemia, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.
Among the 97 studies in Hypoxia with a site in China, this one is the 13th largest by planned enrollment of the 78 interventional ones that give a count, is one of 19 that started in 2026, is one of 63 with no phase, reaches primary completion later than 20 of the 44 other live ones, and was the 80th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18+
General Hospital of Ningxia Medical University · Sites in China
Ages 18+
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
Wenxian Li · Sites in China
Ages 18+
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 1 · Phase 4 3
First in 2009; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 960 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 240 across the 78 interventional studies, 120 across the 19 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 97 have an industry lead sponsor. The 10 most frequent:
General Hospital of Ningxia Medical University is the lead sponsor of 111 studies on the registry; 44 are open to participants now.
General Hospital of Ningxia Medical University has 3 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
15 of the studies in Hypoxia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07748884Second Affiliated Hospital of Wenzhou Medical UniversityComparing Esketamine and Remazolam With Propofol for Breathing Safety in Pediatric Gastroscopy | 2026-12 |
| NCT07395596First Affiliated Hospital of Zhejiang UniversityRemimazolam for Bronchoscopy in High-Risk Patients | 2026-12 |
| NCT07307560Zhejiang UniversityHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | 2026-12-01 |
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT06966934Nanjing First Hospital, Nanjing Medical UniversityNasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients | 2026-12-15 |
Add all 15 to your calendar (.ics) → With an account.
Among the 97 studies in Hypoxia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Using prospective real-world data, this study aims to determine whether the lateral decubitus position reduces the incidence of post-procedure hypoxemia in patients undergoing painless gastroscopy/colonoscopy, thereby providing a simple, non-invasive, and low-cost optimization strategy for clinical practice.
Painless gastroscopy and colonoscopy have become essential modalities for the screening and diagnosis of digestive tract diseases, with their utilization increasing annually. However, hypoxemia remains the most common complication during these procedures, with reported incidences ranging widely from 1.8% to 69%. Severe hypoxemia can lead to adverse outcomes, including arrhythmias, hemodynamic decompensation, and hypoxic brain injury. Consequently, developing effective strategies to prevent hypoxemia in patients undergoing sedation for gastrointestinal (GI) endoscopy is of significant clinical value.
Current clinical research has primarily focused on hypoxemia occurring during the endoscopic procedure itself, whereas there is a paucity of high-quality evidence regarding the incidence and preventive measures of hypoxemia during the recovery phase. Specifically, the impact of body positioning on post-procedural hypoxemia remains largely unexplored. Emerging evidence suggests that the lateral decubitus position significantly reduces the incidence of hypoxemia during adult sedation. Anatomically, in the supine position, residual sedative effects combined with gravity cause the tongue and soft palate-structures lacking bony support-to collapse posteriorly, leading to upper airway obstruction. Conversely, the lateral position helps maintain a patent airway by preventing this collapse and optimizing the ventilation-perfusion (V/Q) matching, thereby stabilizing oxygenation.
Despite this theoretical basis, prospective studies investigating the effect of body positioning on recovery-phase hypoxemia in real-world settings are lacking. Therefore, this study hypothesizes that the lateral decubitus position reduces the incidence of recovery-phase hypoxemia compared to the supine position. Using prospective real-world data, we aim to validate this hypothesis and provide a simple, non-invasive, and cost-effective optimization strategy for clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patient was turned from the predetermined left lateral position to the supine position without a head pillow (head-of-bed elevation at 0 degrees)
Procedure: Supine position group (Group S)
Upon arrival in the post-anesthesia care unit (PACU), the patient was kept in the left lateral decubitus position
Procedure: Lateral decubitus position group (Group L)
Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Lateral Group (Group L) were maintained in the predetermined left lateral position. Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge scoring system; discharge from the PACU occurred when a score of \>9 was a
Upon admission to the Post-Anesthesia Care Unit (PACU), an independent researcher (attending anesthesiologist) assessed the patient using the Ramsay Sedation Scale (1: anxious and agitated; 2: awake, calm, and cooperative; 3: drowsy but responsive to verbal commands; 4: asleep but responsive to tactile stimulation or pain; 5: asleep with a sluggish response to stimulation; 6: deep sleep with no response). Patients in the Supine Group (Group S) were turned from the predetermined lateral position to the supine position without a head pillow (head-of-bed elevation at 0 degrees). Standard monitoring was applied, and nasal cannula oxygen was administered at 2 L/min. If SpO₂ remained \>95% for at least 5 minutes, oxygen was discontinued for observation. To ensure strict adherence to the protocol, an independent researcher continuously monitored and verified patient positioning (corrections were made only if the patient rolled unconsciously). Patients were evaluated using the Aldrete discharge
Incidence of recovery-phase hypoxemia,
Proportion of participants experiencing hypoxemia (SpO₂ ≤ 90% lasting \>10 seconds) during the post-procedure recovery period.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Severe Hypoxemia During Recovery
Proportion of participants experiencing severe hypoxemia, defined as pulse oxygen saturation (SpO₂) \< 85% lasting \>10 seconds during the post-procedure recovery period.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Subclinical Respiratory Depression during Recovery
Proportion of participants experiencing subclinical respiratory depression, defined as any episode of pulse oxygen saturation (SpO₂) in the range of 90% to \<95% (inclusive of 90%, exclusive of 95%) during the post-procedure recovery period.
Time frame: From PACU admission until discharge, assessed up to 30 minutes.
Overall Incidence of Airway Intervention During Recovery
Proportion of participants requiring any grade of airway intervention (increase oxygen flow, chin lift, mask ventilation, or reintubation) during recovery.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Cough Severity Grade During Recovery
Severity of cough assessed during the recovery period, graded as: Grade I: No cough, smooth breathing; Grade II: Single mild cough; Grade III: Multiple coughs lasting \<15 seconds; Grade IV: Continuous coughing lasting ≥15 seconds. Reported as the proportion of participants reaching each grade (I-IV).
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Length of Stay in Post-Anesthesia Care Unit (PACU)
Time from admission to the post-anesthesia care unit (PACU) until discharge criteria are met (modified Aldrete score ≥9 on three consecutive assessments), recorded in minutes.
Time frame: From PACU admission until discharge
Respiratory Comfort Score During Recovery
Patient-reported respiratory comfort assessed using a Numerical Rating Scale (NRS) ranging from 0 (worst discomfort) to 10 (greatest comfort)
Time frame: From PACU admission until discharge, assessed up to 30 minutes
PACU Nurse Satisfaction Score
Nurse-assessed satisfaction with patient respiratory stability and overall recovery management, rated using a Numerical Rating Scale (NRS) ranging from 0 (lowest satisfaction) to 10 (highest satisfaction), recorded at patient discharge from the post-anesthesia care unit.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Tachycardia During Recovery
Proportion of participants experiencing tachycardia (heart rate \>100 beats/min) during the post-procedure recovery period.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Bradycardia During Recovery
Proportion of participants experiencing bradycardia (heart rate \<50 beats/min) during recovery.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Hypotension During Recovery
Proportion of participants experiencing hypotension (systolic blood pressure \<80 mmHg) during recovery.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Nausea or Vomiting During Recovery
Proportion of participants experiencing nausea (subjective complaint) or vomiting (objective expulsion of gastric contents) during recovery.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Incidence of Laryngospasm During Recovery
Proportion of participants experiencing laryngospasm (acute upper airway obstruction with stridor/inability to ventilate, resolving with intervention) during recovery.
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Prespecified Subgroup Analyses
Subgroup analyses will be conducted to explore heterogeneity of treatment effects on the primary outcome (incidence of recovery-phase hypoxemia) across baseline categories: Demographics: age (\<65 vs ≥65 years), sex, body mass index (BMI) category; Clinical characteristics: ASA physical status (I-II vs III), smoking/alcohol history, Mallampati classification (I-II vs III-IV); Procedural factors: endoscopy type (gastroscopy vs colonoscopy vs combined), preprocedural hypoxemia (room-air SpO₂ ≤90%), history of pulmonary surgery, obstructive sleep apnea (OSA), respiratory comorbidities (asthma/COPD/chronic bronchitis/emphysema/bullae), and intraprocedural hypoxemia (SpO₂ ≤90% \>10 s); Postprocedural sedation: Ramsay Sedation Score (2-6). Effect modification will be tested using interaction terms in regression models (or stratified analysis with Cochran-Mantel-Haenszel test).
Time frame: From PACU admission until discharge, assessed up to 30 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Jun 2026, 1 month.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 1 month is below that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Ningxia Medical University →